Verastem Oncology has presented two-year median follow-up data from the Phase 2 RAMP 201 study showing that the combination of avutometinib capsules and defactinib tablets continued to deliver durable clinical benefit in recurrent low-grade serous ovarian cancer, including in both KRAS-mutated and KRAS wild-type subgroups. The update, presented at the Society of Gynecologic Oncology 2026 Annual Meeting, arrives nearly one year after the United States Food and Drug Administration granted accelerated approval for the regimen in KRAS-mutated recurrent disease and adds longer-term evidence on durability, tolerability, and dose strategy.

What makes this update important is not simply that the efficacy story still looks intact after more follow-up, but that the treatment continues to hold up in a disease setting where durability often matters more than headline response rates. Low-grade serous ovarian cancer is a biologically distinct and relatively chemoresistant malignancy, and it remains one of the clearest examples in gynecologic oncology of a tumor type where conventional cytotoxic options frequently underdeliver. In that context, a targeted doublet that can keep patients on treatment for extended periods with manageable toxicity begins to look less like another niche oncology launch and more like a meaningful attempt to reshape the recurrent treatment paradigm.

Why the two-year follow-up matters more than another response-rate update in recurrent low-grade serous ovarian cancer

The most commercially and clinically relevant part of the Verastem Oncology update is the persistence of benefit over time. The company reported that, in the long-term follow-up cohort, median duration of response remained 31.1 months overall and median progression-free survival was 12.9 months, with the KRAS-mutated subgroup showing a median progression-free survival of 19.6 months. Those are not just attractive oncology datapoints. They suggest that the regimen may be delivering a degree of disease control that can matter in real-world practice for a population that is often younger, lives longer with disease than many ovarian cancer populations, and may cycle through multiple lines of therapy over time.

That durability narrative is especially important because accelerated approvals in oncology often face skepticism when based primarily on response metrics without mature time-based outcomes. Here, the message from Verastem Oncology is that the original efficacy signal has not evaporated with follow-up. Instead, the combination appears to maintain its activity profile over roughly two years of observation in ongoing patients. That does not eliminate uncertainty, but it does make the clinical case more credible as the program moves further into the post-approval period.

There is, however, an important interpretive caution. The long-term dataset is based on 17 patients, a much smaller subset than the primary analysis population of 109 patients. That means the durability findings are encouraging but still selective. Patients remaining on therapy at two years are, by definition, not a random cross-section of the whole study population. They may represent individuals with more favorable disease biology, better tolerability, or stronger treatment sensitivity. Clinicians and regulators tracking this space will likely view the data as supportive rather than definitive.

What the subgroup data reveal about market expansion beyond the current KRAS-mutated label

One of the more interesting parts of the update is the continued signal in KRAS wild-type recurrent low-grade serous ovarian cancer. Verastem Oncology said that 30 percent of patients with KRAS wild-type disease remained on therapy for more than one year, compared with 52 percent of patients with KRAS mutations. The median duration of response in the KRAS wild-type group was 12 months, while median progression-free survival was 12.7 months.

That matters because the current United States label is restricted to adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. The wild-type subgroup data do not change that label today, but they do keep alive a broader strategic question around whether the combination could eventually become relevant beyond mutation-selected use. In rare cancers, commercial opportunity is heavily shaped by how narrow or broad the biomarker gate becomes. A regimen that shows clinically meaningful activity outside the currently approved genomic subgroup may gain more attention from prescribers, trial sponsors, and investors, even if formal regulatory expansion still requires more evidence.

The challenge is that subgroup enthusiasm can run ahead of evidence quality. Five KRAS wild-type patients in the long-term follow-up set is not enough to support bold extrapolation. It is enough, however, to justify continued observation and to reinforce why the confirmatory Phase 3 program will matter so much. Industry observers will likely focus on whether the broader RAMP 301 confirmatory study can establish a clearer role for the doublet across a wider recurrent low-grade serous ovarian cancer population rather than only within the currently approved mutation-defined niche.

Why the approved dose-and-schedule analysis could shape physician confidence more than it appears

The exposure-response analysis may look like a technical footnote, but in practice it could become one of the more important components of the launch narrative. Verastem Oncology said the best therapeutic effect was achieved using the approved dose of avutometinib at 3.2 mg twice weekly plus defactinib at 200 mg twice daily, and that lower avutometinib dosing may reduce treatment-emergent adverse events but could also compromise efficacy. The company also emphasized that toxicities can be monitored and managed with dose interruptions, followed by resumption at the approved dose level.

That is strategically useful because targeted oncology adoption often depends less on whether adverse events exist and more on whether the care team believes those adverse events can be anticipated, managed, and navigated without sacrificing benefit. The most common higher-grade toxicities reported in the broader analysis included skin disorders, gastrointestinal toxicity, liver function test abnormalities, and creatine phosphokinase elevation. None of these are trivial, and some could complicate treatment continuity outside experienced centers. But the company is trying to establish an important distinction from earlier targeted approaches where tolerability friction limited enthusiasm.

In a rare ovarian cancer setting, practical usability matters. If oncologists conclude that dose holds and supportive monitoring can preserve dose intensity without excessive discontinuation, that may improve comfort with the regimen in routine practice. The reported 12 percent discontinuation rate due to adverse events, alongside no new safety signals after two years of follow-up, supports that argument, although broader post-launch experience will still matter more than company-sponsored framing.

What this says about the evolving treatment logic in a chemoresistant ovarian cancer subtype

The broader significance of the avutometinib and defactinib story is that it reflects a deeper shift in how recurrent low-grade serous ovarian cancer is being treated. Historically, this disease has exposed the limitations of applying one-size-fits-all ovarian cancer logic to a biologically unusual subtype. Low-grade serous ovarian cancer tends to behave differently from high-grade disease, responds less well to chemotherapy, and often forces clinicians into a longer game of disease control rather than dramatic short-term tumor shrinkage.

The Verastem Oncology regimen is built around a dual-pathway strategy, targeting MEK pathway signaling while also inhibiting focal adhesion kinase, which is implicated in resistance. Mechanistically, that makes sense in a tumor type where MAPK pathway alterations are common and adaptive resistance has been a recurring problem for single-pathway strategies. The company’s argument, in effect, is that the combination may offer a more durable and resistant-aware approach than prior MEK-led efforts alone.

Whether that becomes a lasting standard will depend on comparative evidence, not mechanism alone. The confirmatory RAMP 301 study, which compares the combination against standard chemotherapy or hormonal therapy in recurrent low-grade serous ovarian cancer with and without KRAS mutation, will be central. Accelerated approval created a commercial opening. Confirmatory data will determine whether that opening becomes a durable franchise or a narrower temporary foothold.

What clinicians, regulators, and competitors are likely to watch next as the confirmatory story develops

The next phase of scrutiny will likely focus on four issues. First, can the confirmatory trial reproduce the durability and progression-free survival advantage in a larger, more representative population? Second, will tolerability remain manageable outside specialist centers that are more accustomed to intensive targeted therapy monitoring? Third, can the company convert mutation-linked approval into broader clinical relevance without overextending the current evidence base? And fourth, how durable is physician enthusiasm in a rare disease market where treatment habits can change slowly?

Regulatory watchers will also note that the current approval remains contingent on verification of clinical benefit in a confirmatory trial. That caveat is not unusual in oncology, but it is a reminder that the present label is not the final verdict. From a commercial perspective, Verastem Oncology now has the difficult middle-stage task many oncology companies face after accelerated approval: translating promising early validation into durable prescriber confidence before the confirmatory clock becomes the dominant story.

The two-year update helps. It strengthens the durability case, supports the approved dose strategy, and suggests the regimen is retaining relevance rather than fading into post-approval silence. But it does not close the book. In recurrent low-grade serous ovarian cancer, where the bar is shaped as much by long-term disease control and tolerability as by response rates, the combination of avutometinib and defactinib looks more credible today than it did at launch. The real test now is whether that credibility can survive scale, confirmation, and broader clinical use.

  AVMAPKI FAKZYNJA, avutometinib, defactinib, KRAS mutation, low-grade serous ovarian cancer, RAMP 201, RAMP 301, recurrent ovarian cancer, Verastem Oncology